The sequencing costs for a 20,000 - sample
study at current prices exceed the entire budget of any one center.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and
price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering
prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or
at all, for new and
current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical
studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock
price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Hawkins says
studies from his supporters say a solar plant
at the base would produce electricity far below
current prices, helping business and industry in the state that have been hurt by high power
prices.
To match the
current prices of high - quality blood products the process would have to become
at least fivefold more cost - effective, Douay notes in a recent
study published in Biotechnology Journal.
Bingaman's bill follows many of the recommendations spelled out in NRC's
study, which says
current practices
at the Bureau of Land Management (BLM) are distorting the market
price.
The
study goes on to find that the majority of homeowners in danger of foreclosure could afford to rent their
current house
at a fair market
price, which makes the proposed legislation viable.
Anyone who thinks that the bounce means that the
current bear market is over would do well to
study the behavior of bear markets past (quite aside from simply looking
at the plethora of data about the economy in general, the cyclical nature of long - run corporate earnings and
price - earnings multiples over the same cycle).
A major recent
study found that those needs could readily be met with only wind, water and solar power,
at consumer
prices no higher than
current energy systems.
The organization began accepting ethereum donations to its own ethereum address in August as part of a
study on smart contracts and has raised about $ 600 - worth of ether
at current prices.